Physician profile
Mark C Strickland
NPI 1538110325
$7,228.49
in general payments reported to CMS, 2019-2025
27 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $40.32 · 2021: $799 · 2022: $1,134 · 2023: $1,451 · 2024: $1,825 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,254.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $973.34 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $863.91 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $720.94 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $592.66 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $575.57 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $559.69 | 2021-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $360.85 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Neurocrine Biosciences, INC. | $358.64 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $313.73 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $302.69 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $266.95 | 2020-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $228.28 | 2023-2024 | Qelbree, Qelbree |
| Eisai INC. | $158.94 | 2021 | |
| Sunovion Pharmaceuticals INC. | $156.11 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $138.57 | 2024-2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $112.05 | 2022-2025 | Wellbutrin, Aplenzin |
| Tempus Ai, INC | $97.09 | 2024 | |
| Ironshore Pharmaceuticals INC. | $85.02 | 2022-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $84.57 | 2021-2023 | Belsomra |
| Corium, LLC | $63.37 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $47.89 | 2022-2023 | Spravato |
| Avadel Cns Pharmaceuticals, LLC | $39.39 | 2025 | Lumryz |
| Sage Therapeutics, LLC | $36.09 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $35.17 | 2025 | Jornay Pm |
| Tris Pharma INC | $28.52 | 2023 | Dyanavel Xr |
| Noven Therapeutics, LLC | $15.20 | 2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $13.26 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.